← All trials
NCT06080854
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2023
- Primary completion
- Jun 6, 2025
- Completion date
- Jun 6, 2026
- First posted
- Oct 12, 2023
- Last posted
- Oct 12, 2023
- Enrollment
- 108
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing UniversityLead sponsor
- Nanjing Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Soochow UniversityCollaborator
- Second Military Medical UniversityCollaborator
- Shanghai Xuhui District Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.